• References (50)
  • Citations (0)
Published on Jun 7, 2018in The New England Journal of Medicine70.67
C. Corpechot7
Estimated H-index: 7
(University of Paris),
Olivier Chazouillères49
Estimated H-index: 49
(University of Paris)
+ 30 AuthorsChristine Silvain28
Estimated H-index: 28
(University of Paris)
Abstract Background Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which are agonists of peroxisome proliferator–activated receptors, in combination with ursodeoxycholic acid, have shown potential benefit in patients with this condition. Methods In this 24-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 100 patients who had had an inadequate response to...
Published on Jan 1, 2018in Hepatology14.97
Julie K. Heimbach42
Estimated H-index: 42
(Mayo Clinic),
Laura Kulik46
Estimated H-index: 46
(NU: Northwestern University)
+ 6 AuthorsJorge A. Marrero47
Estimated H-index: 47
(UTSW: University of Texas Southwestern Medical Center)
Author(s): Heimbach, JK; Kulik, LM; Finn, RS; Sirlin, CB; Abecassis, MM; Roberts, LR; Zhu, AX; Murad, MH; Marrero, JA
Published on Jan 1, 2018in The American Journal of Gastroenterology10.24
A. Reig3
Estimated H-index: 3
Pilar Sesé1
Estimated H-index: 1
Albert Parés51
Estimated H-index: 51
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response
Published on Nov 6, 2018in Hepatology14.97
Keith D. Lindor94
Estimated H-index: 94
(ASU: Arizona State University),
Christopher L. Bowlus39
Estimated H-index: 39
(University of California, Berkeley)
+ 2 AuthorsMarlyn J. Mayo23
Estimated H-index: 23
(UTSW: University of Texas Southwestern Medical Center)
Published on Oct 1, 2017in The Lancet Gastroenterology & Hepatology
David Jones51
Estimated H-index: 51
(University of Newcastle),
Pol Boudes4
Estimated H-index: 4
+ 33 AuthorsJoseph A. Odin23
Estimated H-index: 23
(ISMMS: Icahn School of Medicine at Mount Sinai)
Summary Background Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid. Seladelpar is a potent, selective agonist for the peroxisome proliferator-activated receptor-delta (PPAR-δ), which is implicated in bile acid homoeostasis. This first-in-class study evaluated the anti-cholestatic effects and safety of seladelpar in patients with an inadequate response to ursodeoxycholic acid. Methods The study was a 12-week, double-blind,...
Published on Jul 1, 2017in Journal of Hepatology18.95
Gideon M. Hirschfield46
Estimated H-index: 46
Ulrich Beuers55
Estimated H-index: 55
+ 4 AuthorsChristoph Schramm39
Estimated H-index: 39
Summary Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goal...
Published on Aug 18, 2016in The New England Journal of Medicine70.67
Frederik Nevens62
Estimated H-index: 62
(Katholieke Universiteit Leuven),
Pietro Andreone41
Estimated H-index: 41
(UNIBO: University of Bologna)
+ 29 AuthorsUlrich Beuers55
Estimated H-index: 55
(UvA: University of Amsterdam)
BackgroundPrimary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or death. Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients with this disease. MethodsIn this 12-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to urso...
Published on Mar 1, 2016in Hepatology14.97
Marco Carbone17
Estimated H-index: 17
Stephen J. Sharp64
Estimated H-index: 64
+ 20 AuthorsKate D. Williamson7
Estimated H-index: 7
The biochemical response to ursodeoxycholic acid (UDCA)—so-called “treatment response”—strongly predicts long-term outcome in primary biliary cholangitis (PBC). Several long-term prognostic models based solely on the treatment response have been developed that are widely used to risk stratify PBC patients and guide their management. However, they do not take other prognostic variables into account, such as the stage of the liver disease. We sought to improve existing long-term prognostic models ...
Cited By0
View next paperBezafibrate as Second-Line Treatment of Primary Biliary Cholangitis